摘要
糖尿病肾病(diabetic kidney disease,DKD)是糖尿病微血管并发症,是导致终末期肾衰的常见原因,是2型糖尿病患者发病和死亡的主要原因之一。最近越来越多的研究集中在新型降糖药物对肾脏的获益,GLP-1受体激动剂是一类新的降糖药物,可改善血糖水平,降低血压,减轻体质量,减少尿蛋白,延迟DKD的发生或进展。因此本文对GLP-1受体激动剂的肾脏保护作用作一总结。
Diabetes kidney disease(DKD) is a microvascular complication of diabetes,a common cause of endstage renal failure,and one of the main causes of morbidity and mortality in patients with type 2 diabetes.Recently,more and more studies have focused on the benefits of new hypoglycemic drugs on the kidney.GLP-1 receptor agonists are a new kind of hypoglycemic drugs,which can improve blood glucose levels,reduce blood pressure,reduce body weight,reduce urinary protein,and delay the occurrence or progression of DKD.Therefore,this article summarizes the renal protective effects of GLP-1 receptor agonists.
作者
黄亚楠
HUANG Ya'nan(Department of Endocrinology,the Second Affiliated Hospital of Wannan Medical College,Wuhu,Anhui Province,241000 China)
出处
《糖尿病新世界》
2022年第14期195-198,共4页
Diabetes New World Magazine
